Wiley-VCH, Weinheim Drug Development for Malaria Cover This systematic overview of antimalarial drug development addresses current challenges and opportuni.. Product #: 978-3-527-34860-2 Regular price: $139.25 $139.25 In Stock

Drug Development for Malaria

Novel Approaches for Prevention and Treatment

Kendrekar, Pravin (Editor)


1. Edition September 2022
384 Pages, Hardcover
250 Pictures (100 Colored Figures)
Handbook/Reference Book

ISBN: 978-3-527-34860-2
Wiley-VCH, Weinheim

Short Description

This systematic overview of antimalarial drug development addresses current challenges and opportunities and presents numerous case studies for the successful development of effective novel antimalarials.

Buy now

Price: 149,00 €

Price incl. VAT, excl. Shipping

Past, Present and Future Drug Development for Malaria

Scientific Challenges and Treatment Opportunities in the Face of Shifting Malaria Epidemiology
Emerging Formulation Technologies against Malaria Resurgence
Targeted Drug Delivery for Malarial Therapy
The Imminent Threat of Antimalarial Drug Resistance
Current Therapies and New Drug Targets for the Future Drug Development of Drug Resistant Malaria

Assays for Antimalarial Drug Discovery
Aminoacyl-tRNA Synthetases as Malarial Drug Targets: A Structural Biology Perspective
Natural Products as a Source for Antimalarial Drug Development Process - An Overview
Mushroom-Derived Products as an Alternative Antimalarial Therapeutics: A Review
Discovery and Trends of 8-Aminoquinoline and 4-Aminoquinoline Classes of Antimalarials
Antimalarial Activity of Novel Class of 1,3-Benzoxaborole Derivatives Containing 1, 3, 4-Oxadiazole Moiety

Recent Advances in Malaria Vaccine Development
Toll-Like Receptor-Based Adjuvants - A Gateway Towards Improved Malaria Vaccination
Pure TLR7 Agonistic BBIQ is a Potential Adjuvant against P. Berghei ANKA Challenge in Vivo
Pravin Kendrekar studied chemistry at Swami Ramanand Teerth Marathwada University (India) and completed his Ph.D. in Organic Chemistry at Nagoya University of Technology (Japan). After post-doctoral work at Ben Gurion University (Israel) and the University of the Free State (South Africa), he joined the Central University of Technology at Bloemfontein (South Africa) in 2017, where he is currently a group leader in the Unit for Drug Discovery Research. The primary focus of his work is in antimalarial therapy.